scholarly journals P3.15-29 Defining the Symptom Burden of Non-Small Cell Lung Cancer

2018 ◽  
Vol 13 (10) ◽  
pp. S1001-S1002
Author(s):  
M. Whisenant ◽  
L. Williams ◽  
V. Vaghani ◽  
Q. Shi ◽  
A. Garcia Gonzalez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Symptom Burden ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer

Lung Cancer ◽  
2019 ◽  
Vol 131 ◽  
pp. 6-13 ◽  
Author(s):  
Maurice Pérol ◽  
Katherine B. Winfree ◽  
Gebra Cuyun Carter ◽  
Zhanglin Lin Cui ◽  
Lee Bowman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Symptom Burden ◽  
Small Cell ◽  
Exploratory Analysis ◽  
Phase Iii ◽  
Small Cell Lung

scholarly journals Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer

2020 ◽  
Author(s):  
Eric Nadler ◽  
Janet L Espirito ◽  
Melissa Pavilack ◽  
Bismark Baidoo ◽  
Ancilla Fernandes
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Service Use ◽  
Egfr Mutation ◽  
Symptom Burden ◽  
Small Cell ◽  
Small Cell Lung

Aim: To evaluate the real-world impact of brain metastases (BM) among patients with EGFR mutation-positive ( EGFRm) metastatic non-small-cell lung cancer (NSCLC). Materials & methods: This retrospective, observational matched cohort electronic health record study assessed adults with EGFRm metastatic NSCLC with/without BM. Results: Among 402 patients split equally between both cohorts (±BM), the majority were Caucasian (69%), female (65%) and with adenocarcinoma (92%). Overall symptom burden and ancillary support service use were higher and median overall survival from metastatic diagnosis was significantly shorter in BM patients (11.9 vs 16 months; p = 0.017). Conclusion: BM in EGFRm NSCLC patients can negatively impact clinical outcomes. New targeted therapies that can penetrate the blood–brain barrier should be considered for treating these patients.

scholarly journals Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non–small cell lung cancer brain metastases

Cancer ◽  
2020 ◽  
Vol 126 (19) ◽  
pp. 4341-4352
Author(s):  
Ariane Steindl ◽  
Sarah Yadavalli ◽  
Katharina‐Anna Gruber ◽  
Maria Seiwald ◽  
Brigitte Gatterbauer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Neurological Symptom ◽  
Symptom Burden ◽  
Small Cell ◽  
Newly Diagnosed ◽  
Small Cell Lung ◽  
Survival Prognosis

scholarly journals Impact of symptom burden in post-surgical non-small cell lung cancer survivors

2013 ◽  
Vol 22 (1) ◽  
pp. 173-180 ◽  
Author(s):  
Amy E. Lowery ◽  
Paul Krebs ◽  
Elliot J. Coups ◽  
Marc B. Feinstein ◽  
Jack E. Burkhalter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Survivors ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Symptom Burden ◽  
Small Cell ◽  
Small Cell Lung

Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial

2021 ◽  
pp. bmjspcare-2020-002838
Author(s):  
Iain Phillips ◽  
Lindsey Allan ◽  
Adele Hug ◽  
Naomi Westran ◽  
Claudia Heinemann ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Weight Loss ◽  
Nutritional Status ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Symptom Burden ◽  
Small Cell ◽  
Nutritional Deficiencies ◽  
Small Cell Lung ◽  
Dietetic Intervention

IntroductionEuropean Society for Clinical Nutrition and Metabolism guidelines recommend that patients with cancer should be screened for malnutrition at diagnosis. The dietetic assessment and intervention in lung cancer study investigated the nutritional status of patients with non-small cell lung cancer (NSCLC) and the need for dietetic intervention.MethodsIn this observational cohort pilot study, patients with stage 3b and 4 NSCLC were assessed prior to starting first line systemic anticancer therapy (SACT) with a range of measurements and questionnaires. We report the outcomes related to the Patient Generated Subjective Global Assessment tool (PG-SGA),Results96 patients were consented between April 2017 and August 2019. The PG-SGA identified that 78% of patients required specialist nutritional advice; with 52% patients having a critical need for dietetic input and symptom management. Results were dominated by symptom scores. As a screening test, one or more symptoms or recent weight loss history had a sensitivity of 88% (95% CI 78.44% to 94.36%) and specificity of 95.24% (95% CI 76.18% to 99.88%) for need for dietetic intervention.ConclusionA large proportion of patients with NSCLC have a high symptom burden and are at risk of malnutrition prior to starting SACT and would benefit from dietetic review. It is imperative that oncologists and healthcare professionals discuss weight loss history and symptoms with lung cancer patients to correct nutritional deficiencies and resolve symptoms prior to starting treatment.

Sign in / Sign up

Export Citation Format

Share Document